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The clinically used antitumor agent mitomycin C (MC) alkylates DNA upon reductive activation, forming six covalent DNA
adducts in this process. This review focuses on diﬀerential biological eﬀects of individual adducts in various mammalian cell
cultures, observed in the authors’ laboratories. Evidence is reviewed that various adducts are capable of inducing diﬀerent cell
death pathways in cancer cells.This evidence is derived from a parallel study of MC and its derivatives 2,7-diaminomitosene (2,7-
DAM) which is the main metabolite of MC and forms two mono-adducts with DNA, and decarbamoyl mitomycin C (DMC),
which alkylates and cross-links DNA, predominantly with a chirality opposite to that of the DNA adducts of MC. 2,7-DAM is not
cytotoxic and does not activate the p53 pathway while MC and DMC are cytotoxic and able to activate the p53 pathway. DMC is
more cytotoxic than MC and can also kill p53-deﬁcient cells by inducing degradation of Checkpoint 1 protein, which is not seen
with MC treatment of the p53-deﬁcient cells. This diﬀerence in the cell death pathways activated by the MC and DMC is attributed
to diﬀerential signaling by the DNA adducts of DMC. We hypothesize that the diﬀerent chirality of the adduct-to-DNA linkage
has a modulating inﬂuence on the choice of pathway.
The mitomycins are a group of highly potent antibiotics,
produced by the microorganism Streptomyces caespitosus,a s
discovered in Japan in the 1950s [1]. The prototype, most
studied member of this group is mitomycin C (1; MC)
(Figure 1). On account of its broad-spectrum antitumor
activity, MC has been widely used in clinical cancer
chemotherapy [2].
MC has been recognized as a classical DNA damaging
agent, on account of its monofunctional and bifunctional
DNA alkylating activity. Early studies have revealed an
extraordinary property of the mitomycins; they were found
to cross-link the complementary strands of DNA in vivo
and in vitro [3]. MC was postulated to have two alky-
lating centers, the 1,2-aziridine and 10-carbamate groups
(Figure 1). The mitomycins were the ﬁrst natural antibi-
otics found possessing DNA cross-linking activity; there
has been only one other natural cross-linker discovered
since, carzinophyllin/azinomycin [4]. Synthetic DNA cross-
linkers have become a paradigm of anticancer treatment,
however.
Our laboratory has elucidated the structure of the DNA
cross-link adduct of MC [5] and ﬁve additional mono-
functional DNA adducts formed in MC-treated tumor cells
as well as their DNA sequence selectivities, as summarized
in several reviews (see, [6] and references therein). The
structures of the six MC adducts are shown in Figure 2.
Numerous synthetic and natural analogs of the mito-
mycins have been discovered and studied; the details of
which are beyond the scope of this review. However, two
closely related derivatives of MC and their DNA adducts are
relevanttothepresentsubject,namely,2,7-diaminomitosene
(2; 2,7-DAM) and 10-decarbamoyl mitomycin C (3; DMC)
(Figure 1). Their DNA adducts are described in the context
of this review as follows.
2,7-DAM is a major metabolite isolated from cells and
tissues treated with MC. It is a byproduct of the reductive
activation of MC required for unmasking MC’s alkylating
activity [7, 8]. Our laboratory found that two of the six
DNA adducts formed in MC-treated cells are derived from
monofunctionalactivationofDNAbythenascentmetabolite2 Journal of Nucleic Acids
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Figure 1: Chemical structures of MC, DMC, and 2,7-DAM. (Reproduced with permission from Chem. Res. Toxicol. 2008, 21, 2370).
of MC, 2,7-DAM [9, 10]. The structures of the two adducts
were determined (5 and 6; Figure 2)[ 10, 11]. When tumor
cells were treated with 2,7-DAM, the two adducts 5 and 6
were formed at high frequency [10]. Surprisingly, 2,7-DAM
was not cytotoxic under aerobic conditions and negligibly
cytotoxic under hypoxic treatment relative to MC [12, 13].
Its adduct 5 was speciﬁcally shown to be noncytotoxic
and nonmutagenic in E. coli and simian kidney cells [14].
Consistent with these ﬁndings, in cell-free systems tem-
plate oligonucleotides containing a single 2,7-DAM-dG-N7
adduct directed selective incorporation of cytosine opposite
to this adduct in primer strands, catalyzed by Klenow (exo-)
DNA polymerase [14]. Although no analogous experiments
were performed with 2,7-DAM adduct 6 the nontoxicity and
nonmutagenicity of the parent drug [14] predict an outcome
similar to that of 5.
Proof for the cross-link adduct as the critical cytotoxic
lesion among the six MC adducts was provided by a study
of 10-decarbamoyl mitomycin C (2; DMC), an artiﬁcial
derivative obtained from MC by chemical removal of the
10-carbamoyl group [15]. DMC has long been regarded as
an innocuous monofunctional MC derivative, incapable of
causing ICLs, on account of lacking its carbamate alkylat-
ing center. Accordingly, in two laboratories, incubation of
p u r i ﬁ e dD N Aa n dc h e m i c a l l ya c t i v a t e dD M Cy i e l d e do n l y
a monofunctional adduct 2a as the major product, with no
evident DNA cross-link adduct detectable [16, 17]. Inconsis-
tent with these ﬁndings, however, DMC was reported to be
slightly more cytotoxic than MC to hypoxic EMT6 mouse
mammary tumor cells as well as to CHO cells [18, 19].
To resolve this paradox, EMT6 cells were treated with MC
or DMC under hypoxia at equimolar concentrations and
the resulting DNA adducts were determined structurally
and quantitatively [20]. DMC treatment generated two
stereoisomeric monoadducts 2a and 2b (1  -alfa and 1  -
beta, resp.) and two ICL adducts, similarly stereoisomeric
at the 1   position 3a and 3b (1  -alfa- and 1  -beta isomers,
resp.)(Figure 3).Inaddition,thecytotoxicitiesofMC,DMC,
and 2,7-DAM were determined [20], conﬁrming the earlier
results described above. Overall, the adduct frequencies with
DMC were much higher (20- to 30-fold) than with MC.
Although DMC monoadducts greatly exceeded DMC ICL
adducts (approximately 10:1 ratio), the latter were equal
or somewhat higher in number than the ICL adducts from
MC. The relatively similar cytotoxicities of MC and DMC
correlated with the relatively similar ICL adduct frequencies
of the two drugs, but not with their relative monoadduct or
total adduct frequencies. This correlation may be regarded as
speciﬁc experimental evidence that in the EMT6 tumor cell
line ICLs rather than monoadducts are the critical factors in
the cell death induced by MC [20].
It is important to note, however, that in sharp contrast
to the two 2,7-DAM monoadducts 5 and 6, the MC
monoadduct 1a a n dM Ca n dD M Cc o m m o nm o n o a d d u c t
2a were shown to be highly inhibitory to phage replica-
tion after transfection in E. coli [21] and strong blocks
of DNA synthesis in cell-free systems [22]. Furthermore,
monoadduct 1a was shown to be nonmutagenic in E. coli.
Thebiologicalexperimentsutilizedtransfectionofsingle-site
adducted M13 phage or synthetic oligonucleotide constructs
in E. coli strains [22].
Isolation and quantitative analysis of DNA adducts of
MC, DMC, and 2,7-DAM formed in tumor cells have been
conducted by the Tomasz lab in collaboration with the
Sartorelli-Rockwell group at Yale University, using almost
exclusively EMT6 mouse mammary tumor cells. Recently,
the number of cell lines was expanded in collaboration with
the Bargonetti group, and a new method of quantitative
analysis of the adducts of MC and DMC was employed,
namely, LC/electrospray tandem mass spectrometry [23]. In
this work Fanconi Anemia-A cells, normal human ﬁbrob-
lasts, MCF-7 human breast cancer cells, and EMT6 mouse
mammary tumor cells were treated with MC or DMC under
identical conditions, then the cellular DNA was isolated and
analyzed for adducts. In addition to the previously known
1  -alfa isomer adducts of MC the analysis included the new
1  -beta stereoisomers from DMC. The results conﬁrmed the
generality of the DMC adduct pattern described above for
EMT6 cells [20] in each cell line (Figure 4). It was concluded
that DMC shows a stereochemical preference of linkage to
the guanine-2-amino group opposite from that of MC; it
forms two stereoisomeric ICL adducts, and its monoadducts
are formed overall at much greater frequencies than its ICLs.
The adduct patterns of the Fanconi Anemia-A cells and the
control healthy ﬁbroblast cells were identical. This work also
provided preliminary evidence for diﬀerential removal of
adducts upon post-treatment incubation of the cells in drug-
free media. However, more work is needed to conﬁrm these
preliminary results.
In response to DNA adducts mammalian cells activate
a complex signal transduction cascade to activate cell cycle
checkpoints, initiate DNA repair, or induce cell death. The
Bargonetti group, in collaboration with the Tomasz group,
has investigated the biological signaling of mitomycin DNA-
adducts using a human tissue culture model [13, 24]. The
studies addressed two key areas: the ability of 2,7-DAM, MC,Journal of Nucleic Acids 3
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Figure 2:ChemicalstructureofsixmajoradductsofreductivelyactivatedMC.(Reproducedwithpermissionfromthereferencein Figure 1.
and DMC to activate the p53 pathway, and the diﬀering
ability of the drugs to induce cell death in either p53-
proﬁcient or p53-deﬁcient cells. The p53 protein is a central
player in the mammalian cellular response to DNA damage
[25]. Following DNA damage the p53 protein is stabilized
and functions as a strong transcriptional activator of genes
that are required for cell cycle checkpoints, DNA repair,
and the induction of cell death [26]. Many cancer cells
have lost this response through sporadic mutations that
occur in the p53 gene and thus the cells become deﬁcient
in the p53-pathway. Over 50 percent of all cancers have
sustained mutations to the p53 DNA binding domain and
for the purposes of this review we will call them p53-
deﬁcient. MC and DMC treatment of mammalian cells
that are p53-proﬁcient results in increased p53 protein,
activation of the p53-mediated transcriptional activation
of p53-pathway genes, and apoptotic cell death [13, 24],
while the noncytotoxic mitomycin derivative DAM does
not activate the p53 protein or the p53 pathway [13]. This
is in strong keeping with the paradigm of DNA damage-
mediated cytotoxicity being associated with the activation
of the p53 pathway in p53-proﬁcient cells. DNA damage
initiates the activation of DNA repair-related kinases ATR,
ATM, Chk1, and Chk2 [27]. Both ATM and ATR kinases
are able to phosphorylate and activate p53. The fact that
2,7-DAM does not cause activation of the p53-pathway
strongly suggests that the noncytotoxic monoadducts that
result following 2,7-DAM treatment (5 and 6)a r eu n a b l e
to activate the DNA damage-associated kinase pathways.
The comparison of the ability of 2,7-DAM, MC and
DMC to activate the p53-pathway demonstrates that 2,7-
DAM monoadducts do not activate this critical checkpoint
pathway while MC- and DMC-mediated crosslinks are
able to do so. DNA interstrand crosslinks (ICLs) are able
to use ATR/Chk1 and the Fanconia anemia pathway to
signal for cellular checkpoints [28]. Therefore, the 2,7-DAM
monoadducts are likely to be repaired using a diﬀerent
pathway.4 Journal of Nucleic Acids
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The ability of mitomycin DNA adducts to sensitize p53-
deﬁcient cancer cells to die has been examined by a compari-
son of the inﬂuence of MC and DMC on human cancer cells.
Cancer cells that are p53-deﬁcient rely on their ATR/Chk1
checkpoint as their last means of survival and if they lose
Chk1theybecomemoresensitivetodeath[29,30].However,
DNA damage can also cause strong activation of ATR that
subsequently results in activation of Chk1 ubiquitination
and targeted proteolysis of the protein [31]. The loss of
Chk1 in p53-deﬁcient cells causes the cells to lose their last
remaining cell cycle checkpoint and the cells then die by
a caspase 2-mediated pathway [32]. In p53-deﬁcient cells
DMC is more cytotoxic than MC [13, 24] and this associates
with a reduction in Chk1 upon DMC but not MC treatment
[24]. Recent work from the Bargonetti and Tomasz groups
suggeststhatincreasedcytotoxicityofDMCrelativetothatof
MC might be due to the variable chirality of the DMCDNA
adducts that activate Chk1-mediated proteolysis [23, 33].
Interstrand crosslinks activate the ATR/Chk1 pathway as
part of their signal transduction response [28]b u tv a r i a b l e
chirality has yet to be proven to diﬀerentially modulate
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Figure 4: Frequencies of DNA adducts formed in MCF-7 human
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DMC (black bars) for 24 hours under aerobic conditions. The
individual frequency values of the bars are indicated above the bar
error limits. Error limits are shown in % relative standard deviation
units.(ReproducedwithpermissionfromthereferenceinFigure 1).
such a pathway. However, it has been shown that Fanconi
anemia proteins and excision repair proteins participate in
recognitionofMCDNAadducts[34].Itwillbeinterestingto
determine if altered chirality of the mitomycin ICL adducts
diﬀerentially recruit the DNA damage signaling machinery
to the DNA. This could be the consequence of a diﬀerence
in the alignment of the 1  -alfa and 1  -beta stereoisomeric
adducts in DNA. Structural studies in coordination with
biochemical techniques to examine speciﬁc DNA-protein
interactions could further explore this hypothesis.
In summary. Using a variety of techniques it has been
possible to assign speciﬁc biological eﬀects to each of the
six DNA adducts of MC in mammalian cell cultures. Critical
in this endeavor was the surprising discovery that DMC was
slightly more cytotoxic than MC in cell cultures and it pro-
duced ICLs which correlated with its cytotoxicity [20]. This
served as proof that the ICL was the major cytotoxic lesion
of MC and DMC. DMC formed 20–30 times more DNA
monoadducts than MC, which were linked to the N2 atom
of guanines with opposite chirality (I
  -beta) to that of MC
(1  -alfa) [23]. Parallel studies of MC and DMC revealed that
DMC is much more cytotoxic to p53-deﬁcient cells than MC
[13,24,33]andwehaveshownthatitiscapableofinducinga
cell death pathway involving proteasome-mediated degrada-
tionofCheckpoint1protein[33].Futurestudiesinourlabo-
ratories aim at elucidating the mechanism of the diﬀerential
cell death pathways of MC and DMC in the context of the
structures of their DNA adducts. More than 50% of human
cancers are deﬁcient for p53 function and contain either p53
mutations or oncogenic proteins that functionally inactivate
p53. Determining how alternative DNA-adduct chirality can
initiate signal transduction pathways for increased cytotoxi-
city in p53-deﬁcient cancers could become a new paradigm
in chemotherapeutic drug discovery.Journal of Nucleic Acids 5
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